Tetrahydrofuran

Tetrahydrofuran

SCHEMBL1007230

C1CCOC1.[Ru].c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
ALDH1A1 P00352 2/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
CRHBP P24387 2/20 0.36
CRHR2 Q13324 2/20 0.36
HTT P42858 1/20 0.36
GAA P10253 3/20 0.35
KDM4E B2RXH2 1/20 0.35
DRD1 P21728 2/20 0.35
PKM P14618 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
FKBP1A P62942 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL4256459 1.00 CYP3A4 (0.57) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL3544589 0.98 CYP3A4 (0.60) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL2014438 0.95 CYP3A4 (0.57) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28244884 0.89 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28163050 0.89 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Tetrahydrofuran SCHEMBL28244765 0.89 CYP3A4 (0.50) CYP3A4TDP1ESR1ESR2ALDH1A1
Dioxane SCHEMBL27471817 0.87 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2LMNA
Oxirane SCHEMBL29388114 0.85 CYP3A4 (0.71) CYP3A4TDP1ESR1ESR2LMNA
Tetrahydrofuran SCHEMBL28355034 0.79 ALDH1A1 (0.36) CYP3A4TDP1ALDH1A1LMNASMN1; SMN2
Cyclohexane SCHEMBL28199422 0.79 CYP3A4 (0.80) CYP3A4TDP1ESR1ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270063-B1 PROCESS FOR PRODUCING HYDROGENATED PRODUCT OF CYCLIC OLEFIN POLYMER PREPARED THROUGH RING-OPENING POLYMERIZATION ZEON CORP (JP) 2016-03-23 EP disclosed
US-9243098-B2 Compound, polymer, cross-linked compound of polymer, and optical element including cross-linked compound CANON KABUSHIKI KAISHA (JP) 2016-01-26 US disclosed
US-20140163175-A1 NOVEL COMPOUND, POLYMER, CROSS-LINKED COMPOUND OF POLYMER, AND OPTICAL ELEMENT INCLUDING CROSS-LINKED COMPOUND CANON KABUSHIKI KAISHA (JP) 2014-06-12 US disclosed
EP-1197509-B1 PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN ZEON CORP (JP) 2011-07-06 EP disclosed
EP-2270063-A2 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization NIPPON ZEON CO., LTD. (JP) 2011-01-05 EP disclosed
US-6908970-B2 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization ZEON CORPORATION (JP) 2005-06-21 US disclosed
US-20030050406-A1 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization ZEON CORPORATION 2003-03-13 US disclosed
EP-1197509-A1 PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN Nippon Zeon Co., Ltd. (JP) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163175-A1 NOVEL COMPOUND, POLYMER, CROSS-LINKED COMPOUND OF POLYMER, AND OPTICAL ELEMENT INCLUDING CROSS-LINKED COMPOUND PCLAF, PCNA, SMC2 CYP3A4 3992/4885TDP1 4354/4885ESR1 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.